Cost-effectiveness of different treat-to-target strategies in rheumatoid arthritis: results from the DREAM registry
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2520-1026
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cost-effectiveness of different treat-to-target strategies in rheumatoid arthritis: results from the DREAM registry ; volume:3 ; number:1 ; day:29 ; month:4 ; year:2019 ; pages:1-9 ; date:12.2019
BMC Rheumatology ; 3, Heft 1 (29.4.2019), 1-9, 12.2019
- Creator
-
van de Laar, Celine J.
Oude Voshaar, Martijn A. H.
Vonkeman, Harald E.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s41927-019-0064-9
- URN
-
urn:nbn:de:101:1-2019051023431114316174
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- van de Laar, Celine J.
- Oude Voshaar, Martijn A. H.
- Vonkeman, Harald E.
- SpringerLink (Online service)
Other Objects (12)
Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry
Treat-to-Target Strategies in Rheumatoid Arthritis: a Systematic Review and Cost-Effectiveness Analysis
Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: results from the DREAM registry
Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort
Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry
Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry
Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry
Is Baricitinib Effective and Safe for Patients with Difficult-to-Treat Rheumatoid Arthritis? Comparative Data with the Rheumatoid Arthritis Group of Rheumatoid Arthritis Not Difficult to Treat
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions
Au Clusters Treat Rheumatoid Arthritis with Uniquely Reversing Cartilage/Bone Destruction
Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry
Treat-to-Target Strategies in Rheumatoid Arthritis: a Systematic Review and Cost-Effectiveness Analysis
Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: results from the DREAM registry
Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort
Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry
Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry
Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry
Is Baricitinib Effective and Safe for Patients with Difficult-to-Treat Rheumatoid Arthritis? Comparative Data with the Rheumatoid Arthritis Group of Rheumatoid Arthritis Not Difficult to Treat
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions
Au Clusters Treat Rheumatoid Arthritis with Uniquely Reversing Cartilage/Bone Destruction
Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry
Treat-to-Target Strategies in Rheumatoid Arthritis: a Systematic Review and Cost-Effectiveness Analysis
Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: results from the DREAM registry
Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort
Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry
Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry
Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry
Is Baricitinib Effective and Safe for Patients with Difficult-to-Treat Rheumatoid Arthritis? Comparative Data with the Rheumatoid Arthritis Group of Rheumatoid Arthritis Not Difficult to Treat
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions